Inion secures R&D (research and development) plans with £30m London IPO (initial public offering) - update
This article was originally published in Clinica
Finnish biodegradable implants developer Inion has succeeded in raising around £33m ($62.3m) before expenses in an initial public offering (IPO) on London's main stock market, the company announced today.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.